Epidemiology Group, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.
Biology and Control of Infectious Diseases Group, Faculty of Exact and Natural Sciences, University of Antioquia, Medellín, Colombia.
PLoS One. 2022 Sep 9;17(9):e0271851. doi: 10.1371/journal.pone.0271851. eCollection 2022.
Diabetes has been associated with an increased risk of complications in patients with COVID-19. Most studies do not differentiate between patients with type 1 and type 2 diabetes, which correspond to two pathophysiological distinct diseases that could represent different degrees of clinical compromise.
To identify if there are differences in the clinical outcomes of patients with COVID-19 and diabetes (type 1 and type 2) compared to patients with COVID-19 without diabetes.
Observational studies of patients with COVID-19 and diabetes (both type 1 and type 2) will be included without restriction of geographic region, gender or age, whose outcome is hospitalization, admission to intensive care unit or mortality compared to patients without diabetes. Two authors will independently perform selection, data extraction, and quality assessment, and a third reviewer will resolve discrepancies. The data will be synthesized regarding the sociodemographic and clinical characteristics of patients with diabetes and without diabetes accompanied by the measure of association for the outcomes. The data will be synthesized regarding the sociodemographic and clinical characteristics of patients with diabetes and without diabetes accompanied by the measure of association for the outcomes.
Update the evidence regarding the risk of complications in diabetic patients with COVID-19 and in turn synthesize the information available regarding type 1 and type 2 diabetes mellitus, to provide keys to a better understanding of the pathophysiology of diabetics.
This study was registered at the International Prospective Registry for Systematic Reviews (PROSPERO)-CRD42021231942.
糖尿病与 COVID-19 患者发生并发症的风险增加有关。大多数研究并未区分 1 型和 2 型糖尿病患者，这两种疾病对应两种截然不同的病理生理疾病，可能代表不同程度的临床损害。
确定 COVID-19 合并糖尿病（1 型和 2 型）患者与 COVID-19 无糖尿病患者的临床结局是否存在差异。
将纳入无地域限制、性别或年龄限制的 COVID-19 合并糖尿病（1 型和 2 型）患者的观察性研究，其结局为与无糖尿病患者相比住院、入住重症监护病房或死亡。两名作者将独立进行选择、数据提取和质量评估，第三位审稿人将解决差异。将对伴有结局关联度量的糖尿病和无糖尿病患者的社会人口学和临床特征进行数据综合。将对伴有结局关联度量的糖尿病和无糖尿病患者的社会人口学和临床特征进行数据综合。
更新有关 COVID-19 糖尿病患者并发症风险的证据，并综合有关 1 型和 2 型糖尿病的现有信息，为更好地理解糖尿病患者的病理生理学提供关键信息。
本研究在国际前瞻性系统评价登记册（PROSPERO）-CRD42021231942 中进行了登记。
